Small-cap DataMeds AI lifts quarterly sales 50% on pharmacy weight-loss drug volumes

DataMeds AI (NASDAQ: MEDS) reported third-quarter 2026 revenue of $2.7m, up from $1.8m in the second quarter. The 50% increase is sequential rather than year-on-year, and the absolute figure is small. The company credits the rise to GLP-1 medicines dispensed through its Corexa Pharmacy business.

The headline profit needs separate treatment. DataMeds booked net income of $10.5m for the quarter, which it says came mainly from extinguishing debt and litigation liabilities rather than from trading. The profit therefore says little about the underlying earnings power of the pharmacy operation, and the revenue line is the better guide to commercial momentum.

The company also said it regained compliance with Nasdaq listing requirements on 19 October. Separately, it has begun offering compounded peptides under an FDA policy of enforcement discretion dated 30 October 2026. The material available to CompePharma does not describe the policy's scope or name the peptides involved, so the revenue potential of the new line cannot be assessed.

DataMeds additionally announced a mobile app, a licence for a GLP-1 platform called REBOOT, a non-binding memorandum of understanding with a health maintenance organisation, and the acquisition of Helomics. No financial terms or timelines were disclosed for any of these.